inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ years 3. negative human immunodeficiency virus (hiv 1 \& 2) and hepatitis b and c test results 4. negative immunoglobulin m (igm) and immunoglobulin g (igg) sars-cov-2 antibodies through enzyme immunoassay test result 5. negative covid-2019 reverse transcriptase-polymerase chain reaction (rt-pcr) test result at the screening visit (72 hours prior to visit 1 \[day 1\]) 6. no covid-2019 in the medical history 7. history of no contact with covid-2019 persons within at least 14 days before the enrolment (according to subjects) 8. consent for using effective methods of contraception during the entire trial 1 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 11. no acute infectious and/or respiratory diseases within at least 14 days before the enrolment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ years 3. negative human immunodeficiency virus (hiv 1 \& 2) and hepatitis b and c test results 4. negative immunoglobulin m (igm) and immunoglobulin g (igg) sars-cov-2 antibodies through enzyme immunoassay test result 5. negative covid-2019 reverse transcriptase-polymerase chain reaction (rt-pcr) test result at the screening visit (72 hours prior to visit 1 \[day 1\]) 6. no covid-2019 in the medical history 7. history of no contact with covid-2019 persons within at least 14 days before the enrolment (according to subjects) 8. consent for using effective methods of contraception during the entire trial 1 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 11. no acute infectious and/or respiratory diseases within at least 14 days before the enrolment.

inclusion criteria: written informed consent of a subject to participate in the trial males and females aged 18+ years negative human immunodeficiency virus (hiv 1 & 2) and hepatitis b and c test results negative immunoglobulin m (igm) and immunoglobulin g (igg) sars-cov-2 antibodies through enzyme immunoassay test result negative covid-2019 reverse transcriptase-polymerase chain reaction (rt-pcr) test result at the screening visit (72 hours prior to visit 1 [day 1]) no covid-2019 in the medical history history of no contact with covid-2019 persons within at least 14 days before the enrolment (according to subjects) consent for using effective methods of contraception during the entire trial 1 negative urine pregnancy test at the screening visit (for child-bearing age women) no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history no acute infectious and/or respiratory diseases within at least 14 days before the enrolment.

inclusion criteria: written informed consent of a subject to participate in the trial males and females aged 18+ years negative human immunodeficiency virus (hiv 1 & 2) and hepatitis b and c test results negative immunoglobulin m (igm) and immunoglobulin g (igg) sars-cov-2 antibodies through enzyme immunoassay test result negative covid-2019 reverse transcriptase-polymerase chain reaction (rt-pcr) test result at the screening visit (72 hours prior to visit 1 [day 1]) no covid-2019 in the medical history history of no contact with covid-2019 persons within at least 14 days before the enrolment (according to subjects) consent for using effective methods of contraception during the entire trial 1 negative urine pregnancy test at the screening visit (for child-bearing age women) no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history no acute infectious and/or respiratory diseases within at least 14 days before the enrolment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ years 3. negative human immunodeficiency virus (hiv 1 & 2) and hepatitis b and c test results 4. negative immunoglobulin m (igm) and immunoglobulin g (igg) sars-cov-2 antibodies through enzyme immunoassay test result 5. negative covid-2019 reverse transcriptase-polymerase chain reaction (rt-pcr) test result at the screening visit (72 hours prior to visit 1 [day 1]) 6. no covid-2019 in the medical history 7. history of no contact with covid-2019 persons within at least 14 days before the enrolment (according to subjects) 8. consent for using effective methods of contraception during the entire trial 1 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 11. no acute infectious and/or respiratory diseases within at least 14 days before the enrolment.

inclusion criteria: 1. written informed consent of a subject to participate in the trial 2. males and females aged 18+ years 3. negative human immunodeficiency virus (hiv 1 & 2) and hepatitis b and c test results 4. negative immunoglobulin m (igm) and immunoglobulin g (igg) sars-cov-2 antibodies through enzyme immunoassay test result 5. negative covid-2019 reverse transcriptase-polymerase chain reaction (rt-pcr) test result at the screening visit (72 hours prior to visit 1 [day 1]) 6. no covid-2019 in the medical history 7. history of no contact with covid-2019 persons within at least 14 days before the enrolment (according to subjects) 8. consent for using effective methods of contraception during the entire trial 1 9. negative urine pregnancy test at the screening visit (for child-bearing age women) 10. no evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history 11. no acute infectious and/or respiratory diseases within at least 14 days before the enrolment.